Ocriplasmin

Identification

Summary

Ocriplasmin is a proteolytic enzyme used to treat symptomatic vitreomacular adhesion by dissolving the protein matrix responsible for the adhesion between the vitreous and macula.

Brand Names
Jetrea
Generic Name
Ocriplasmin
DrugBank Accession Number
DB08888
Background

Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Recombinant Enzymes
Protein Chemical Formula
C1214H1890N338O348S14
Protein Average Weight
27250.0 Da
Sequences
>Protein sequence for the truncated heavy chain
APSFDCGKPQVEPKKCPGR
>Protein sequence for the light chain 
VVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAH
QEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECF
ITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDS
GGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN
Download FASTA Format
Synonyms
  • Microplasmin
  • Microplasmin (synthetic human)
  • Ocriplasmin
  • Ocriplasmina
  • Recombinant human microplasmin

Pharmacology

Indication

Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Ocriplasmin has proteolytic activity against protein components of the vitreous body and the vitreoretinal interface (VRI) (e.g. laminin, fibronectin and collagen), thereby dissolving the protein matrix responsible for the vitreomacular adhesion (VMA).

TargetActionsOrganism
AFibronectin
cleavage
Humans
NAlpha-2-macroglobulin
ligand
Humans
NAlpha-2-antiplasmin
ligand
Humans
Absorption

Because of the small dose administered (0.125 mg), ocriplasmin is not expected to be in the systemic circulation following injection. Within 30 minutes after injection, levels of ocriplasmin in the vitreous are 12 mcg/mL. 24 hours after injection, levels in the virtreous are 0.5 mcg/mL

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Ocriplasmin is quickly inactivated by protease inhibitor α2-antiplasmin or α2-macroglobulin.

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

The most commonly reported reactions (≥ 5%) in patients treated with ocriplasmin were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
No interactions found.
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
JetreaSolution2.5 mg / mLIntravitrealThrombogenics Nv2013-11-202020-03-10Canada flag
JetreaInjection, solution1.25 mg/1mLIntravitrealThromboGenics Inc.2017-09-182021-01-31US flag
JetreaInjection, solution0.375 mg/0.3mlIntravitrealInceptua Ab2016-09-08Not applicableEU flag
JetreaInjection, solution2.5 mg/1mLIntravitrealThrombo Genics2012-10-312017-09-18US flag
JetreaSolution1.25 mg / mLIntravitrealThrombogenics Nv2019-05-082020-03-20Canada flag
JetreaInjection, solution, concentrate0.5 mg/0.2mlIntravitrealInceptua Ab2016-09-08Not applicableEU flag

Categories

ATC Codes
S01XA22 — Ocriplasmin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
7V6HE3DM5A
CAS number
1048016-09-6

References

General References
Not Available
KEGG Drug
D09646
PubChem Substance
347910381
RxNav
29998
ChEMBL
CHEMBL2095222
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ocriplasmin
FDA label
Download (392 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentVitreomacular Adhesion / Vitreomacular Traction (VMT)2
3CompletedTreatmentSymptomatic Vitreomacular Adhesion (VMA)1
3CompletedTreatmentVitreomacular Adhesion2
3CompletedTreatmentVitreomacular Adhesion Including Macular Hole1
2CompletedTreatmentDiabetic Macular Edema (DME)1
2CompletedTreatmentEye Diseases / Vitreomacular Traction Maculopathy1
2CompletedTreatmentFocal Vitreomacular Adhesion1
2CompletedTreatmentFocal Vitreomacular Adhesion / Neovascular Age-Related Macular Degeneration (nAMD)1
2CompletedTreatmentStroke, Acute1
2CompletedTreatmentVitrectomy therapy3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntravitreal0.375 MG/0.3ML
Injection, solutionIntravitreal1.25 mg/1mL
Injection, solutionIntravitreal2.5 mg/1mL
Injection, solution, concentrateIntravitreal0.5 mg/0.2ml
SolutionIntravitreal1.25 mg / mL
SolutionIntravitreal2.5 mg / mL
Solution, concentrateIntravitreal0.5 MG/0.2ML
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Cleavage
General Function
Protease binding
Specific Function
Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, an...
Gene Name
FN1
Uniprot ID
P02751
Uniprot Name
Fibronectin
Molecular Weight
262623.095 Da
References
  1. Tsui I, Pan CK, Rahimy E, Schwartz SD: Ocriplasmin for vitreoretinal diseases. J Biomed Biotechnol. 2012;2012:354979. doi: 10.1155/2012/354979. Epub 2012 Oct 14. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Ligand
General Function
Tumor necrosis factor binding
Specific Function
Is able to inhibit all four classes of proteinases by a unique 'trapping' mechanism. This protein has a peptide stretch, called the 'bait region' which contains specific cleavage sites for differen...
Gene Name
A2M
Uniprot ID
P01023
Uniprot Name
Alpha-2-macroglobulin
Molecular Weight
163289.945 Da
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Ligand
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Serine protease inhibitor. The major targets of this inhibitor are plasmin and trypsin, but it also inactivates matriptase-3/TMPRSS7 and chymotrypsin.
Gene Name
SERPINF2
Uniprot ID
P08697
Uniprot Name
Alpha-2-antiplasmin
Molecular Weight
54565.32 Da

Drug created on May 29, 2013 06:29 / Updated on September 16, 2021 13:04